China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou Royaltech Med Co., Ltd to establish bacterial (Listeria) and mRNA drug platform technologies. The collaboration aims to integrate both firms’ resources and capabilities, though financial terms were not disclosed.
Company Profiles
- Porton Biologics: Founded in 2018, Porton offers an end-to-end gene and cell therapy CDMO service platform covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy, and live bacterial therapy. Services span from library establishment to cGMP production and commercialization.
- Royaltech Med: Specializes in cancer immunotherapy vaccines and next-generation cellular immunotherapy technologies. Its pipeline includes RT201, a first-in-class macrophage tumor vaccine targeting tumor antigens, currently in clinical trials.
Strategic Outlook
The partnership will leverage Porton’s CDMO expertise and Royaltech’s immunotherapy platforms to advance bacterial and mRNA drug development, aiming to accelerate clinical applications in oncology.-Fineline Info & Tech
